An exclusive interview with Maciej Gamrot and Przemysław Tadla, members of the management board at Medicalgorithmics, has been featured in “Strefa Inwestorów” – a prominent Polish financial medium dedicated to companies listed on the Warsaw Stock Exchange. The interview provides valuable insights into the company’s current operations and its growth plans in the years ahead.
Key takeaways from the interview:
- Medicalgorithmics is currently undergoing a strategic transformation of its business model, transitioning from a company offering a closed product ecosystem to a specialized AI solutions provider for the medical sector.
- The recent investment from Biofund has strengthened Medicalgorithmics’ financial position, ensuring a solid foundation for investment in research and development initiatives.
- A major focus of the company’s research and development efforts is the VCAST technology, being developed by its subsidiary: Kardiolytics. This innovative technology is set to revolutionize the diagnosis of coronary artery disease by leveraging AI-driven analysis of heart computed tomography data.
- Medicalgorithmics will continue to expand its PocketECG ecosystem, offering comprehensive and precise diagnostic solutions for heart arrhythmias.
To read the full interview with the management teaof Medicalgorithmics, please visit: https://strefainwestorow.pl/artykuly/wywiady/20230613/medicalgorithmics-maciej-gamrot-przemyslaw-tadla